Avesthagen Final

AVESTHAGEN LIMITED
Ethos
Indias leading integrated systems biology platform company

focus
convergence between food, pharma and population genetics develop products for predictive, preventive and personalized healthcare
AVESTHAGEN LIMITED
Business Model | Product Strategy

Nutrition Healthcare
Systems Biology
Predictive Preventive Personalized
Technologies | Products
bioPharmaceuticals
bioNutrition
bioAgriculture
AVESTHAGEN LIMITED
Business Model | Alliances Strategy
bioPharmaceuticals
Avesthagen Platform
Alliances
bioAgriculture
bioNutrition
AVESTHAGEN LIMITED
Business Model | Growth through Partnership

Early Research Product Development Trials & Validation
Production
Marketing
bioNutrition
Lab Scale
Process Development
API Production
Regulatory Approvals
Marketing
bioPharmaceuticals
Early Research
Crop Development
Trials
Regulatory
Marketing
bioAgriculture
Avesthagen
Subsidiary(ies)
Partner(s)
AVESTHAGEN LIMITED
Business Model | Product Development Strategy

2008 2010+ 2015+
Predictive / Preventive (p) Clinically Validated Bioactives (Fx)
Personalized (P)
bioNutrition
- pDx + Fx - pDx + Rx
Nutrigenomics pDx + PFx + PRx
AVESTAGENOME
Biomarker Discovery
Predictive Diagnostics (pDx)
pDx + PVx + PRx*
bioPharmaceuticals
* Includes biopharmaceuticals and bioactives products
pDx + PVx + Rx
AVESTHAGEN LIMITED
Group Structure | Global Footprint
AVESTHAGEN LIMITED
Group Structure | Shareholding
AVESTHAGEN LIMITED
Board of Directors
Chairperson Dr. Villoo Morawala-Patell Vice Chairman Mr. Darius E. Udwadia Directors Mr. Emmanuel Rougier Mr. Jochen Ebert Prof. Marc Van Montagu Mr. Nadir Godrej Mr. K Ravindra Mr. Koen Wentink Dr. Helle Bechgaard
Founder and Managing Director, AVESTHAGEN LIMITED
Founding partner of Udwadia & Udeshi, Solicitors & Advocates
Deputy CEO, Groupe Limagrain Managing Director, Danone India Pvt. Ltd. Founding Director of IPBO Managing Director of Godrej Industries Chief Risk Officer, ICICI Venture Fund Chief of Logistics, AVESTHAGEN LIMITED Vice-Chairman, Dankse Bank, Denmark Institute of Biotechnology, Cambridge University Institute of Biochemistry, Cambridge University
Mrs. Farah Morawala-Patell-Socha

Ms. Sanaya Morawala-Patell
AVESTHAGEN LIMITED
Scientific Advisory Board

Prof Rita Colwell Distinguished Professor, University of Maryland,John Hopkins Institute of Public Health, Previously Director of the National Science Foundation, USA Director General, Science Foundation Ireland, Previously Director of EMBO Honorary Professor, Department of Biochemistry Indian Institute of Science, Previously Director of IISc. Director General Danone Research Deputy Director, J Craig Venter Institute Distinguished Biotechnology Fellow & Advisor Translational Health Science & Technology Institute Department of Biotechnology, National Institute of Immunology Cellular Organisation & Signalling National Centre for Biological Sciences
Prof. Frank Gannon Prof. G. Padmanabhan Dr. Sven Thormahlen Dr. Robert L. Strausberg Prof. N.K. Ganguly
Prof. Satyajit Mayor
Dr. Jean-Pierre Isal Dr. Chris Bowler
Independent Consultant (Previously Senior VP, Quintiles)

Molecular Marine Biology, Ecole Normale Suprieure, Paris
AVESTHAGEN LIMITED
Management Team
Dr. Villoo Morawala-Patell Mr. Samaresh Parida Mr. Koen Wentink Mr. Bruce Murdoch Mr. Pierre Socha Mr. Supriyo Guha Dr Rajesh Ullanat Founder and CMD Chief Operating Officer Chief Logistics Officer Chief Business Officer Vice-President, Corporate Development Company Secretary Chief Scientific Officer, bioPharmaceuticals Chief Scientific Officer, Science & Innovation Chief Scientific Officer, BioNutrition Vice-President, Operations and Corporate Affairs
Dr Sami Guzder
Dr Renuka Jain Dr. Anil Ram Chauhan
AVESTHAGEN LIMITED
Key Shareholders
Financial Investors
ICICI Ventures India
Fidelity International
New York Life USA
Strategic Investors
Danone France
Tata Industries India
Limagrain France
Cipla India
bioMrieux France
Godrej Industries India
AVESTHAGEN LIMITED
IP Portfolio
bioAgriculture bioNutrition Metabolic Engineering
Diagnostics
180 Inventions
bioPharma
AVESTHAGEN LIMITED
IP Portfolio
Patents
Avesthagen has been granted 9 patents across different countries, the details of which is provided below. Additionally, a total of 346 patent applications are pending today in different jurisdictions.
Group bioAgriculture bioNutrition bioPharmaceuticals Science and Innovation TOTAL Inventions 46 75 13 46 180 Application/Filings 74 145 98 29 346
Type of Application Patents Granted
Indian 2
USA 2
EU 1
Australia 2
S. Africa 1
Korea 1
Total 9
AVESTHAGEN LIMITED
IP Portfolio
Copyrights 7 copyrights have been granted, of which 5 are in India and 2 in the United States. Another 8 copyright applications are pending. The distribution of the copyrights across the business is given below.
Business Copyrights Granted Copyright Applications
AGT General 1 4
bioNutrition 3 4
bioAgriculture 1 -
S&I 2 -
Total 7 8
AVESTHAGEN LIMITED
IP Portfolio
Trademarks 46 trademarks have been Registered and a further 49 trademark applications are pending in India. The distribution of these across the business is given below.
Business Trademarks Registered Trademark Applications TOTAL
AGT General 5 17 22
bioNutrition 40 23 63
bioAgriculture 1 6 7
S&I 2 2
bio Pharma 1 1
Total 46 49 95
bioNutrition Strategy & Product Pipeline
bioNutrition
Mission Statement
Global nutrition platform specializing in the discovery, development and marketing of branded and clinically validated plant based bioactives aimed at degenerative conditions.
In the near future, Avesthagen will bring new products for B2C and B2B markets developed in collaboration with private / public partners
With the convergence of Avestagenome and Drug Discovery efforts new personalised bioactives will be launched
bioNutrition
Strategy | Proprietary Tools
ADePt TM
Availability of extensive databases that include a widerange of products used in traditional systems of medicine practiced in India and SEA and a compendium of herbal medicines used across the world. MetaGrid TM A proprietary methodology called MetaGridTM, which is based on the use of sophisticated high-throughput instrumental analysis. Effective Clinical R&D model Validation of the activity of compositions using tissue specific gene expression profiling (micro-arrays) and highly targeted cell and animal models of human diseases.
bioNutrition
Strategy | R&D
MetaGridTM
bioNutrition
Strategy | Product Pipeline
bioNutrition
Strategy | Branded Bioactives

Health Condition
Brand Name
Status
Functionality
Lowers Glycemic Index Insulin mimetic and sensitization activity Insulin mimetic and sensitization activity Lowers Glycemic Index and Insulin sensitization Insulin mimetic and sensitization activity Insulin sensitization
Food Application
Snacks
Teestar
ASPAND
Diabetes
Clinical trials completed

Pre-clinical trials completed Pre-clinical trials completed
Beverage and snacks Beverage and snacks Snacks and beverages Snacks and beverages Snacks and beverages
Govad
Gosh Mohor
Pre-clinical trials completed Pre-clinical trials completed Pre-clinical trials completed
bioNutrition
Strategy | Branded Bioactives
Health Condition
Brand Name
Status Pre-clinical trials completed Pre-clinical trials completed Pre-clinical trials completed
Functionality
Promotes bone formation Promotes bone formation Reduces bone resorption Lowers cholesterol
Food Application
Snacks and beverages Snacks Snacks and beverages Beverages and Snacks Snacks and beverages
Bone Health
Cardiovascular Health Antioxidant
Pre-clinical trials completed
Clinical trials completed
Cell rejuvination
bioNutrition
Strategy | Product Positioning
2008
2010+
2015+
FFM
Bioactives Abbreviated Trials
Bioactives Clinically Validated
Foods
Health Foods Abbreviated Trials
Functional Foods Clinically Validated
Nutraceuticals
OTC drugs Abbreviated Trials
Rx Clinically Validated
bioNutrition
Business Model
Early Research Product Development Trials & Validation
Production
Marketing
Discovery, development and marketing of branded therapeutic nutritional bioactives aimed at degenerative conditions, especially diabetes and weight management, CVD, osteoarthritis and osteoporosis, stress and cancer. Joint product optimization and development Joint testing and validation with marketing partner Exclusive Manufacturing rights to Avesthagen Marketing of product Avesthagen entitled to royalties and milestone payments / success fees Joint IP ownership
Avesthagen Subsidiary(ies) Partner(s)
bioNutrition
Strategy | B2B - Collaborations
For specified product categories
bioNutrition
Strategy | B2C - Functional Foods
Functional Foods using active ingredients developed by Avesthagen (launch May 2008)
Muesli & Breakfast Cereals (7 variants) Whole Wheat Crackers (6 variants) Bars (4 variants) Ethnic Snacks (end 2008)
bioNutrition
bioNutrition

Whole Wheat Crackers with TEESTAR Salient features

Reduces blood glucose levels Maintains optimum body weight 100% Natural Zero trans fat Ideal ratios of SFA: MUFA: PUFA Good source of dietary fibers Prebiotic Suitable for pre diabetics Suitable for calorie conscious No added artificial colours, flavors or preservatives
Approx. Nutrition facts (per 100g)

Energy (kcals) 384.02 Carbs (g) 53 Protein (g) 11.46 Fat (g) 10 Fiber (g) 18.09
Recommended serving: 4-5 crackers twice a day
bioNutrition

Whole Wheat Crackers Value Proposition
A healthy and natural treat, Good Earth Whole Wheat Crackers, are light, heartfriendly and easy to digest. High Fibre content from wheat bran used in its original form. Zero Trans fat which means lower blood cholesterol levels and reduced risk of cardiovascular problems. An ideal healthy snack to be eaten at anytime of the day
Plain Wheat, Ground Garlic, Roasted Sesame, Crushed pepper, Flaked Chilli & Toasted Jeera
bioNutrition

Breakfast Cereals
bioNutrition

Good Earth Muesli Bars
Value Proposition
On-the-go snack, keeps you going until your next meal. Natural fruits and almonds provide micronutrients essential for maintaining good health. High proteins from skimmed milk and soy protein repair damaged cells owing to intense physical activity Presence of sugars and assimilated carbohydrates result in instant and sustained energy. Available in three variants -, Apple Cinnamon , Cocoa Dates Almonds and Orange Peel Raisins Dates
bioNutrition
Strategy | B2C - OTC
Launched in US Market Launch in India : mid 2008 EU Launch : end 2008
bioNutrition
Strategy | B2C - OTC
bioNutrition
Market | Industry Dynamics
Fundamental changes in the dynamics of the healthcare industry are the driving growth of the nutrition industry :
An increasingly aging population
The increasing cost of healthcare

The growing trend towards self-medication The growing consumer interest in alternatives to pharmaceuticals
Nutrition is being increasingly recognized as a major avenue for healthcare

Consumer is increasingly aware of the linkage between health and nutrition The Dietary Supplement and Health and Education Act (DSHEA)
bioNutrition
Market | Big Four Health Conditions

Cost Distribution by Disease State (2005) 17% 74% of Total Costs 9% 10% 11% 20% 33% 100%
Source: CDC, US Dept of Health & Human Services
CVD Cardiovascular Diesease
Cancer Cancer
Diabetes Diabetes
Obesity Over-weight & Obesity
Chronic
Other Other Chronic
All Other All Other
Total Total Healthcare Healthcare Cost
cost
$653
$396
$226
$209
$ Billions
$190
$342
$2,016
bioNutrition
Markets
Functional foods The global market is estimated to be USD 85 billion in size in 2006, growing at a rate of 8-9% p.a. USA, Europe and Japan are the largest markets for functional foods.
Dietary supplements The global market for dietary supplements is estimated at USD 68 billion (2006), and is exhibiting a growth rate of 4-5% per annum. The US is the largest market for dietary supplements, with an estimated market size of USD 22 bn.
Global functional ingredient sales Global ingredient sales are estimated at USD 9.4 billion for 2006. This constitutes USD 7.6 bn. as supply to the supplement market, and USD 1.8 billion as supply to the functional food market.
Source: Nutrition Business Journal November 2007
bioPharmaceuticals Strategy & Product Pipeline
bioPharmaceuticals
Mission Statement
Strategy for biosimilars though partnering for cost effective healthcare focusing on mammalian blockbusters with high entry barrier.
In the near future, Avesthagen will bring new biopharma technologies and products developed in collaboration with private / public partners
With the convergence of Avestagenome and Drug Discovery efforts new personalised biopharmaceuticals will be launched
bioPharmaceuticals
Business Model
Lab Scale Process Development API Production Regulatory Approvals
Marketing
Co-funded Development program for pipeline of Biosimilars with high entry barriers Avesthagen responsible for development and manufacturing Partner responsible for marketing of product Avesthagen entitled to 20% royalties on net sales of the products IP shared between partners equally Manufacturing facilities for biologicals (being setup in India + Acquisition in Germany + dialogues on with other Asian countries)
bioPharmaceuticals
Product Pipeline
bioPharmaceuticals
Revenues
bioPharmaceuticals
Revenues
bioPharmaceuticals
Manufacturing | Sites
Phase 1 Setup of pilot scale manufacturing facility To be completed by third quarter 2008 Capacity 200 L bioreactor (2 low/medium dosage molecules) cGMP qualified facilities 2 x 200 L & 1000 L (Germany and Malaysia)
Phase 2 Setup of large scale manufacturing facility Capacity 10,000 lt bioreactor with DSP infrastructure Will be completed by late 2010 cGMP qualified Will be certified by the USFDA Acquisition of manufacturing plant an option being investigated
cGMP facility Berlin, Germany
cGMP facility, Bangalore, India
bioPharmaceuticals
Manufacturing | Networking of project sites
Indian Operations
German Operations
Bangalore PDL
Cell line Development Process Development 2 Projects at a time
Bangalore GMP
Pre-clinical material Clinical material 50L / 150L One project
Berlin PDL
Cell line Development Process Development 1 Project at a time (currently)
Kleinmachnow GMP
Pre-clinical material Clinical material 50L / 200L (Two) projects at a time
CMO
1000 L
Innobiologics PDL
Process Development 30L One project
Innobiologics GMP
Pre-clinical material Clinical material 30L / 300L / 1000L One project
3rd Party Operations
Malaysian Operations
bioPharmaceuticals
Market | Entry Strategy
The Total world market for Biological products in 2007 was valued at Euros 60 billion and market value of the Biosimilar product portfolio is Euros 15 billion.
The Therapeutic segments that Avesthagen s Biosimilar pipeline are directed, which includes, Autoimmune disease, Cancer and Blood disorders are valued at Euros 70 billion worldwide and INR 4 billion in India.
bioPharmaceuticals

2011 - 2018 2010 - 2012
2009 - 2012
AVESTHAGEN
BIOSIMILARS
INDIAN MARKETS EUR 600 mil BRIC MARKETS EUR 2 bil EU/US/REGULATED EUR 15 bil
bioPharmaceuticals
The first products will be launched in India in 2009 and 2010 followed by BRIC countries and then EU and USA once Patents begin to expire on the products. The Market entry strategy for India and BRIC countries is to market through the largest Pharmaceutical company in India- Cipla Ltd (market share of 6%.) Cipla will participate in Clinical Phases, Regulatory approval, Formulation and Marketing. Revenue will come from API sales and Royalties. The Market entry strategy for EU, USA and Regulated markets is to secure strong market partners early in the Clinical Development and Regulatory process to market beginning 2011/12. Revenue will come from Licensing, Milestones, API sales and Royalties.
bioPharmaceuticals
Collaborations
bioPharmaceuticals
Collaborations
Ongoing discussions Medium sized Pharma company based in Vienna, EU Large Biopharma company (No.2) based in EU Large Biopharma CMO and supplier based in Basel, EU
New discussions
Large Pharma company moving into Biologics, US
bioAgriculture Strategy & Product Pipeline
bioAgriculture
Mission Statement
Avesthagen Seed Promise: To build credibility with farmers and commitment to excellence while growing as a profitable enterprise.
To improve productivity in Agriculture and develop technologies that address global environmental challenges to achieve a sustainable future through a fine blend of food, feed, fibre and fuel.
bioAgriculture
Strategy | Market entry
2008
2010+
2015+
Food & Feed
Animal Husbandry Nutrition / Additives Feeding / Sheltering
Environment Adjusted Crops Nutrition-FITTM : DHA, ALA, Lycopene Stress Resistance : Drought-FITTM, Salinity-FITTM Hybrid-FITTM
Other Applications
Industrial Applications Plastics, Food Stuffs, Adhesives
Fibre Applications Equipments, Clothing Construction
Petroleum Applications Fuel, Oil Lubricants
bioAgriculture
Business Model | Environment Adjusted Crops

Early Research Crop Development
Trials
Regulatory
Marketing
Development of Environment Adjusted plants for food, feed, fuel and fibre Avesthagen takes ideas to proof-of-concept stage and partners for development of products Joint green house testing and field validation with a) marketing partner or b) Atash Seeds Pvt Ltd (subsidiary) Avesthagen entitled to licensing fees, milestone payments / success fees and royalties Joint marketing of product Joint IP ownership
bioAgriculture
Market | Global Area of Biotech Crops
bioAgriculture
Market | Domestic Markets
Source : International Seed Federation, 2008
bioAgriculture
Product Pipeline | 1st generation (Atash Seeds)
Field Crop Varieties Field Crop Hybrids
Wheat, Rice and Peas Rice, Cotton, maize, Sunflower, sorghum, pearl millet, and tur dal Tomatto, Chilli, Brinjal, Cabbage, Cauliflower, Beans, Gourds, Greens and Melons
Vegetable Hybrids
bioAgriculture
Product Pipeline | 2nd generation
Public - Private Collaborations
Hybrid
Pigeonpea (ICRISAT) Millet (ICRISAT) Drought Rice (UAS)
bioAgriculture
Product Pipeline | 3rd generation
Drought-FIT TM Rice Pearl Millet
Nutrition-FITTM Sunflower
Marker Assisted Selection / Breeding

Barley
Mustard Maize Tomato Rice
Hybrid-FIT Rice Tomato
TM
Salinity-FITTM
Bio-fuels
Rice Jatropha
bioAgriculture
Nutrition-FITTM
High Anti oxidant Rice (Non GM)

Collection of over ninety lines Currently in field for multiplication Analysis for antioxidant content, 2008 Large scale cultivation, 2008 High antioxidant Rice based product, 2009 Market Launch Globally, 2009 Estimated rice production 2008, 423 Million Tons Coloured Rice Market Globally: Over 100 M USD
bioAgriculture
Nutrition-FITTM
High Lycopene Tomato Analysis for antioxidant content, 2007 A range of 250-500% increase in Lycopene Currently analysing fruits of third generation Selection of plant and tissue culture, 2008 Permission for Protected Cultivation trial, 2008 Large scale Greenhouse cultivation, 2009 High Lycopene tomato puree product development, 2009 GM Lycopene product development, 2009 Market Launch 2011 Market Size 2009 for lycopene sales will surpass $26 million, according to Frost & Sullivan
bioAgriculture
Drought-FITTM
Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~2011 Multigene gene Indica rice (GM) ~ 2012
bioAgriculture
Drought-FITTM
Drought tolerant Indica Rice (MAB) Checked in All India Trials Best Material so identified for drought tolerance Currently in mass production Variety Product launch in 2009 Hybrid Product Launch in 2011 Rice Variety seed market, Rice Hybrid seed market,
bioAgriculture
Drought-FITTM
Single gene Japonica rice (GM) Four Generations Checked in Greenhouse Strip trials permission to RCGM, 2008 Large Scale Field Trail, 2009 Commercial Seed Production 2010 Launch of GM drought tolerant Transgenic Japonica rice, 2011 Estimated market for drought tolerant variety, 50 M USD
bioAgriculture
Drought-FITTM
Multi gene Indica Hybrid rice (GM) Generating T0s, parent for hybrid 2008 Greenhouse trials, 2009 Hybrid Seed Production, 2010 Strip trials permission to RCGM, 2011 Large Scale Field Trail, 2012 Commercial Seed Production 2013 Launch of GM drought tolerant Transgenic Hybrid Indica rice, 2013 Estimated market for drought tolerant hybrids, over ~100 M USD
bioAgriculture
Hybrid-FITTM
Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~ 2013
bioAgriculture
Product Pipeline | 3rd generation Summary Nutrition-FITTM

High Anti oxidant Rice (Non GM): 2009 High Lycopene products: 2011
Drought-FIT TM

Drought tolerant Indica Rice (MAB) ~ 2009 Single gene Japonica rice (GM) ~ 2011 Multigene gene Indica rice (GM) ~ 2012
Hybrid-FITTM

Male Sterile slender long grain rice ~ 2011 Male Sterile Tomato ~ 2011 Male Sterile Wheat ~2013
bioAgriculture
Atash Seeds
bioAgriculture
Collaborations
bioAgriculture
BioperceptTM
Normal plastic BioperceptTM
05/05
bioAgriculture
BioperceptTM
Biopercept TM addressing a need
The twenty first century will be defined as a plastic age. Mankind uses more plastics than iron & steel. Single use plastic bags are the single largest source of solid waste pollution in the world today. These bags float around and stay in our air, water and land for a thousand years. Often termed as white pollution, countries around the world have taken steps to control this problem.
In India and in the Middle East, Avesthagen's presence and its strategic relationship with Limagrain has enables us to taken steps to introduce BioperceptTM fully biodegradable and compostable plastic bags.
Science & Innovation Predictive, Preventive & Personalised Healthcare
Science & Innovation
Mission Statement
Science & Innovation focus on Preventive, Predictive and Personalised Healthcare through Systems Biology
Science & Innovation is core to Avesthagen's business of science strategy, an integrated platform of biotechnology and bioinformatics delivering Innovation with Systems Biology.
Science & Innovation enables new product development and Partnership building.
Predictive, Preventive & Personalised Healthcare

- Systems Biology - Avestagenome Project TM - Natural Product Drug Discovery
Avesthagen leads global change
Biochemistry Therapeutics / Diagnostics One Size fits all drugs
Systems Biology Theranostics Personalized medicine
Treating Sickness
Aging Food for survival Fossil fuels
Preventing Sickness
Stem Cells Therapy Food for health Alternative Energy
Systems Biology
Confluence of Technology, Tools and Knowledge
New Tools for Drug Discovery

1st generation 2nd generation 3rd generation
genomics/ proteomics cell pharmacology/ molecular biology natural products and derivatives genetic engineering receptors enzyme Biotech drugs lipid lowerers ACE-inhibitors H2-antagonists beta blockers NSAIDS psychotropics penicillins sulphonamides aspirin
New Therapeutic Cycles
serendipity
chronic degenerative disease associated with ageing, inflammation, cancer
1900
1950
1960
1970
1980
1990
2000
2010
2020
2030
2040
Source: CMS, Lehman Brothers research
drugs against targets identified from disease genes
Food Pharma Convergence
Avesthagen | Product Development Strategy

Diabetes Type 2: Whats Becoming Possible?
Source : Burrill & Company
Food Pharma Convergence
Avesthagen | Product Development Strategy

2008 2010+ 2015+
Predictive / Preventive (p) Clinically Validated Bioactives (Fx)
Personalized (P)
bioNutrition
- pDx + Fx - pDx + Rx
AVESTAGENOME
Biomarker Discovery
Predictive Diagnostics (pDx)
pDx + PVx + PRx*
bioPharmaceuticals
* Includes biopharmaceuticals and bioactives products
pDx + PVx + Rx

- Systems Biology - The AvestagenomeTM Project - Natural Product Drug Discovery
The AvestagenomeTM Project
Overview
Predictive, Preventive and Personalized Healthcare:
A systems biology study of the Parsis to determine the genetic basis of longevity and age-related disorders.
Overview
Ideal Population
The Parsis are well defined small population of less than 70,000 individuals in India Concentrated in and around Mumbai Well documented genealogical charts demonstrating an unbroken lineages for 30 generations Generations of marriage within the community has resulted in

increased positive traits - greater longevity diseases - Parkinsons disease, stroke, heart disease, specific cancers, and Alzheimers disease.
Ideal population to study the interplay of multiple genes, environment and health factors
Markets
Market value of biomarker discovery
There are as many as 17 groups of diseases and wellness aspects in our project
Disease
Cancer Arthritis Diabetes
Market value
$35bn (Datamonitor report 2005-01-06) $10bn (IMS health reports 2007) $15bn (Leaddiscovery report 2006-03-27)
Other diseases
Heart diseases Kidney Diseases Lung Diseases Multiple Sclerosis Prostate Disease Genetic Disorders Glucose-6-Phosphate Dehydrogenase Deficiency Thyroid Diseases Blood Pressure Systemic Lupus Erythematosis Mental Illness Gynecological Problems Neurological Disorders (Parkinsons) Asthma
Markets | Age related conditions

Arthritis: Market and Opportunity
Disease Facts: Poor prognosis leads to: - Aggressive treatment - Development of disease modifying antirehumatic drugs (DMARD) Market needs: - Arthritis Market value is $10bn - There is a need to develop new strategies for Biomarker identification & nutritional products to prevent and/or treat Arthritis
IMS health reports 2007, Frost & Sullivan 2004 and Nature Reviews Drug Discovery 4, 11-12 (January 2005)
Markets | Age related conditions

Projected Alzheimers Disease Prevalence
Conditions | Cancers prevalence
Distribution of cancer cases in Parsis and the general population of Mumbai, 2002-04. (Data obtained from the Bombay Cancer Registry, Mumbai)
Strategy | R&D
Phase 1 Systems Biology approach for Biomarker Discovery (eg. Osteoarthritis) Blood collection Archival
DNA and RNA
Plasma & Serum
Clinical & scientific Data
HTS Genetic sequence Analysis (Genome, SNP etc.)
Metabolomics
Bioinformatics
Gene Expression Microarray
Proteomics
Disease information
Biomarkers
Strategy | R&D
Phase 2 Biomarkers to Drug Discovery
Validation of Biomarkers
Assay Development
Bioactive/Drug Screening
Nutritional/wellness products & Drugs for Healthcare
Biomarkers for Longevity
- Preventive and Predictive Healthcare - Wellness and nutritional products - Personalized Healthcare
Disease Biomarkers
Strategy | R&D
Decision Support Tools: Assess Risk Refine Assessment Predict/Diagnose Monitor Progression Predict Events Inform Therapeutics
Baseline Risk Disease Burden
Initiating Events
Earliest Molecular Detection
Earliest Clinical Detection
Typical Current Intervention 1/reversibility Cost
Time Baseline Risk
Preclinical Progression
Dynamic Genomics: Gene Expression Proteomics Metabolomics
Disease Initiation and Progression Therapeutic Decision Support
Sources of New Biomarkers:
Stable Genomics: SNPs Haplotype Mapping Gene Sequencing
Strategy | R&D
Analyzing the Molecular Profiles (Biosignatures) of Body Functions in Health and Disease
The Molecular Basis of Biological Processes
The Molecular Heterogeneity of Disease
Individual Genetic Variation
Alterations in Disease
Disease Subtypes
Pharmacogenetics New Targets for Dx, Rx, Vx
Disease Predisposition
New Targets for Dx, Rx, Vx
Right Rx for Disease
PDx PRx
Strategy | R&D
Avestagenome work flow for biomarker identification
2007-08 2008-09 2009-10 2010-11 2011-12 2012-13 Study design Database construction Blood collection Genotyping Association Mapping Sequenom Analysis Transcriptome profiling Metabolome Plasma proteins Stem Cells Molecular Diagnostics
Outcomes | Healthcare
Outcomes | Safer, More Effective Drugs
Outcomes | Nutrition
Nutrigenomics
The same way that drugs work well for some people and not others, some people
- Eat high fat diets and not show evidence of atherosclerosis. WHY? - Have high cholesterol and not die of heart attacks. WHY?
Outcomes | Nutrigenomics
Source : Nature Publishing
Outcomes | Nutrition
The Avestagenome Project To understand an individuals response to nutrition through the analysis of their unique genetic make up bioNutrition To match an individual to his food and allows development of safe and effective dietary treatments
Strategy | Business Model

Blood Collection Biomarkers Discovery Biomarkers Validation Rx, Fx, Vx, Dx Development Production & Marketing
Biobank
Tie-up with Global players in Diagnostics, Vaccines, Pharma and Nutrition as well as Public bodies Joint product optimization and development
Joint testing and validation with marketing partner

Partner responsible for marketing of product Full IP ownership with Avesthagen Commercial used of the outcomes to be based on Territories, Health Conditions and Uses/Products. Avesthagen entitled to royalties and milestone payments / success fees
Avesthagen Partner(s)
Strategy | Collaborations
Diagnostics
Clinicals
Nutrigenomics
Technology Partners

- Systems Biology - Avestagenome Project TM - Natural Product Drug Discovery
Natural Product Drug Discovery
Strategy | Screening of FFM bioactives

Processing Experiments Bio-assays guided Fractionation Structure Determination
Initial Bioactive Sample Bioactive Concentrate
Pure Bioactive Compound Known Compounds Novel Bioactive Compound
Evaluation of natural SAR Shotgun synthesis of derivatives Scale-up purification Medicinal Chemistry
Potential Lead Development Track Candidate
bioNutrition
Science & Innovation
Strategy | Antarctica Project
Strategy | Stem Cells

Whats happening in Stem Cells?
Human nerve stem cells transplanted into rats' damaged spinal cords have survived
Found: Stem Cells Responsible for Pancreatic Cancer

Mother's Stem Cells Passed to BabySuggests Possible Way to Treat Diabetes Stem Cell Lines Generated from Amniotic Fluid Multipotent Adult Progenitor Cells (MAPCs) Regenerate Blood in Mice
Treatments for Alzheimers and Multiple Sclerosis

Regeneration and repair of periphery nerves Repair damaged heart muscle and improve cardiac function Stem-cell transplantation for refractory or relapsing lymphomas
Strategy | Stem Cells
Research Programmes
Avesthagenome Cancer Cardiovascular Hepatoxicity Macular/Optic Nerve Regeneration Red Blood Cells Adult Stem Cells
This mouse offers proof that researchers can create embryonic stem cells without using an egg. It grew from an embryo containing cells that had been reprogrammed to an embryonic state. Source: Whitehead Institute for Biomedical Research
Strategy | Capabilities
BIOMARKERS & TARGETS Study Design & Sample collection Genotyping - Sequencing Transcriptome (Gene Expression) Metabolite Identification Proteome Profiling Statistical Analysis Bioinformatics
CHEMISTRY & ASSAYS Medicinal Chemistry Analytical Chemistry Synthetic Chemistry Computational Chemistry Chemioinformatic BioChemical Assays Cell Based Assays Stem Cells (Screening)
CLINICAL & REGULATORY Preclinicals & Clinicals Regulatory & Ethical approvals
Strategy | Business Model
Drug Discovery
Collaborations
Financials
AVESTHAGEN LIMITED
Profit & Loss
AVESTHAGEN LIMITED
Profit & Loss
AVESTHAGEN LIMITED
Funds Requirement
AVESTHAGEN LIMITED
Milestones
Avesthagen is a 650 employee company well-regarded worldwide for its uniqueness and leading position in India
Closure of Series-C early 2007 & IPO scheduled for 2008-2009

Product driven group and launch of new ones in 2007 across our businesses. Strong and innovative IP portfolio with more than 151 inventions, 341 Patent applications and 100 applications on Copyrights & Trademarks Profitable for three consecutive years (excl. exceptional items) with strong top line growth Solid back-up from strategic and financial investors Long-term commitments from partners / clients Multiple top international certifications and awards Significant infrastructure expansion Strong management team
THANK YOU

Avesthagen Final

Hochgeladen von

Dokumentinformationen

Copyright

Verfügbare Formate

Dieses Dokument teilen

Dokument teilen oder einbetten

Freigabeoptionen

Stufen Sie dieses Dokument als nützlich ein?

Sind diese Inhalte unangemessen?

Copyright:

Verfügbare Formate

Avesthagen Final

Hochgeladen von

Copyright:

Verfügbare Formate

AVESTHAGEN LIMITED

Indias leading integrated systems biology platform company

Business Model | Product Strategy

Business Model | Alliances Strategy

Business Model | Growth through Partnership

Business Model | Product Development Strategy

Predictive / Preventive (p) Clinically Validated Bioactives (Fx)

Nutrigenomics pDx + PFx + PRx

Predictive Diagnostics (pDx)

pDx + PVx + PRx*

Group Structure | Global Footprint

Group Structure | Shareholding

Founder and Managing Director, AVESTHAGEN LIMITED

Founding partner of Udwadia & Udeshi, Solicitors & Advocates

Mrs. Farah Morawala-Patell-Socha

Scientific Advisory Board

Prof. Satyajit Mayor

Dr. Jean-Pierre Isal Dr. Chris Bowler

Independent Consultant (Previously Senior VP, Quintiles)

ICICI Ventures India

New York Life USA

Tata Industries India

Godrej Industries India

bioAgriculture bioNutrition Metabolic Engineering

Type of Application Patents Granted

Business Copyrights Granted Copyright Applications

Business Trademarks Registered Trademark Applications TOTAL

bioNutrition Strategy & Product Pipeline

Strategy | Proprietary Tools

Strategy | Product Pipeline

Strategy | Branded Bioactives

Clinical trials completed

Pre-clinical trials completed Pre-clinical trials completed Pre-clinical trials completed

Strategy | Branded Bioactives

Cardiovascular Health Antioxidant

Pre-clinical trials completed

Clinical trials completed

Strategy | Product Positioning

Bioactives Abbreviated Trials

Bioactives Clinically Validated

Nutrigenomics pDx + PFx + PRx

Health Foods Abbreviated Trials

Functional Foods Clinically Validated

Nutrigenomics pDx + PFx + PRx

OTC drugs Abbreviated Trials

Nutrigenomics pDx + PFx + PRx

Avesthagen Subsidiary(ies) Partner(s)

Strategy | B2B - Collaborations

For specified product categories

Strategy | B2C - Functional Foods

Strategy | B2C - Functional Foods

Strategy | B2C - Functional Foods

Approx. Nutrition facts (per 100g)

Recommended serving: 4-5 crackers twice a day

Strategy | B2C - Functional Foods

Strategy | B2C - Functional Foods

Strategy | B2C - Functional Foods

Strategy | B2C - OTC

Launched in US Market Launch in India : mid 2008 EU Launch : end 2008

Strategy | B2C - OTC

Market | Industry Dynamics

An increasingly aging population

The increasing cost of healthcare

Nutrition is being increasingly recognized as a major avenue for healthcare